Regulation of pulmonary surfactant by the adhesion GPCR GPR116/ADGRF5 requires a tethered agonist-mediated activation mechanism

  1. James P Bridges
  2. Caterina Safina
  3. Bernard Pirard
  4. Kari Brown
  5. Alyssa Filuta
  6. Ravichandran Panchanathan
  7. Rochdi Bouhelal
  8. Nicole Reymann
  9. Sejal Patel
  10. Klaus Seuwen
  11. William E Miller
  12. Marie-Gabrielle Ludwig  Is a corresponding author
  1. Cincinnati Children's Hospital Medical Center, United States
  2. Novartis, Switzerland
  3. University of Cincinnati, United States
  4. Novartis, United States

Abstract

The mechanistic details of the tethered agonist mode of activation for the adhesion GPCR ADGRF5/GPR116 has not been completely deciphered. We set out to investigate the physiologic importance of autocatalytic cleavage upstream of the agonistic peptide sequence, an event necessary for NTF displacement and subsequent receptor activation. To examine this hypothesis, we characterized tethered agonist-mediated activation of GPR116 in vitro and in vivo. A knock-in mouse expressing a non-cleavable GPR116 mutant phenocopies the pulmonary phenotype of GPR116 knock-out mice, demonstrating that tethered agonist-mediated receptor activation is indispensable for function in vivo. Using site-directed mutagenesis and species swapping approaches we identified key conserved amino acids for GPR116 activation in the tethered agonist sequence and in extracellular loops 2/3 (ECL2/3). We further highlight residues in transmembrane7 (TM7) that mediate stronger signaling in mouse versus human GPR116 and recapitulate these findings in a model supporting tethered agonist:ECL2 interactions for GPR116 activation.

Data availability

Source data for the modeling is provided (coordinates of the model)

Article and author information

Author details

  1. James P Bridges

    Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    No competing interests declared.
  2. Caterina Safina

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    Competing interests
    Caterina Safina, is employed by and shareholder of Novartis Pharma AG..
  3. Bernard Pirard

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    Competing interests
    Bernard Pirard, is employed by and shareholder of Novartis Pharma AG..
  4. Kari Brown

    Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    No competing interests declared.
  5. Alyssa Filuta

    Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    No competing interests declared.
  6. Ravichandran Panchanathan

    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, Cincinnati, United States
    Competing interests
    No competing interests declared.
  7. Rochdi Bouhelal

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    Competing interests
    Rochdi Bouhelal, is employed by and shareholder of Novartis Pharma AG..
  8. Nicole Reymann

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    Competing interests
    Nicole Reymann, is employed by and shareholders of Novartis Pharma AG.
  9. Sejal Patel

    Novartis Institutes for Biomedical Research, Novartis, Cambridge, United States
    Competing interests
    Sejal Patel, is employed by and shareholder of Novartis Pharma AG..
  10. Klaus Seuwen

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    Competing interests
    Klaus Seuwen, is employed by and shareholder of Novartis Pharma AG..
  11. William E Miller

    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, Cincinnati, United States
    Competing interests
    No competing interests declared.
  12. Marie-Gabrielle Ludwig

    Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland
    For correspondence
    marie-gabrielle.ludwig@novartis.com
    Competing interests
    Marie-Gabrielle Ludwig, is employed by and shareholder of Novartis Pharma AG..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7799-4782

Funding

National Heart, Lung and Blood Institute of the NIH (HL131634)

  • Caterina Safina
  • Bernard Pirard

This work was funded in part by the NIH grant listed above.

Ethics

Animal experimentation: All animal procedures were performed under protocols (AS2842_05_22; JPB) approved by the Institutional Animal Care and Use Committee of National Jewish Health in accordance with National Institutes of Health guidelines.

Copyright

© 2022, Bridges et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,144
    views
  • 259
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James P Bridges
  2. Caterina Safina
  3. Bernard Pirard
  4. Kari Brown
  5. Alyssa Filuta
  6. Ravichandran Panchanathan
  7. Rochdi Bouhelal
  8. Nicole Reymann
  9. Sejal Patel
  10. Klaus Seuwen
  11. William E Miller
  12. Marie-Gabrielle Ludwig
(2022)
Regulation of pulmonary surfactant by the adhesion GPCR GPR116/ADGRF5 requires a tethered agonist-mediated activation mechanism
eLife 11:e69061.
https://doi.org/10.7554/eLife.69061

Share this article

https://doi.org/10.7554/eLife.69061

Further reading

    1. Cell Biology
    Fabian Link, Sisco Jung ... Brooke Morriswood
    Research Article

    The actin cytoskeleton is a ubiquitous feature of eukaryotic cells, yet its complexity varies across different taxa. In the parasitic protist Trypanosoma brucei, a rudimentary actomyosin system consisting of one actin gene and two myosin genes has been retained despite significant investment in the microtubule cytoskeleton. The functions of this highly simplified actomyosin system remain unclear, but appear to centre on the endomembrane system. Here, advanced light and electron microscopy imaging techniques, together with biochemical and biophysical assays, were used to explore the relationship between the actomyosin and endomembrane systems. The class I myosin (TbMyo1) had a large cytosolic pool and its ability to translocate actin filaments in vitro was shown here for the first time. TbMyo1 exhibited strong association with the endosomal system and was additionally found on glycosomes. At the endosomal membranes, TbMyo1 colocalised with markers for early and late endosomes (TbRab5A and TbRab7, respectively), but not with the marker associated with recycling endosomes (TbRab11). Actin and myosin were simultaneously visualised for the first time in trypanosomes using an anti-actin chromobody. Disruption of the actomyosin system using the actin-depolymerising drug latrunculin A resulted in a delocalisation of both the actin chromobody signal and an endosomal marker, and was accompanied by a specific loss of endosomal structure. This suggests that the actomyosin system is required for maintaining endosomal integrity in T. brucei.

    1. Cell Biology
    Georgia Maria Sagia, Xenia Georgiou ... Sofia Dimou
    Research Article Updated

    Membrane proteins are sorted to the plasma membrane via Golgi-dependent trafficking. However, our recent studies challenged the essentiality of Golgi in the biogenesis of specific transporters. Here, we investigate the trafficking mechanisms of membrane proteins by following the localization of the polarized R-SNARE SynA versus the non-polarized transporter UapA, synchronously co-expressed in wild-type or isogenic genetic backgrounds repressible for conventional cargo secretion. In wild-type, the two cargoes dynamically label distinct secretory compartments, highlighted by the finding that, unlike SynA, UapA does not colocalize with the late-Golgi. In line with early partitioning into distinct secretory carriers, the two cargoes collapse in distinct ER-Exit Sites (ERES) in a sec31ts background. Trafficking via distinct cargo-specific carriers is further supported by showing that repression of proteins essential for conventional cargo secretion does not affect UapA trafficking, while blocking SynA secretion. Overall, this work establishes the existence of distinct, cargo-dependent, trafficking mechanisms, initiating at ERES and being differentially dependent on Golgi and SNARE interactions.